RESUMO
Lupus anti-coagulant hypoprothrombinemia syndrome (LAHPS) is a rare condition that can be difficult to treat. It increases the risk of thrombosis and bleeding due to the presence of lupus anti-coagulant and factor II deficiency, respectively. There are a limited number of cases described in the literature. Herein we describe a case of LAHPS with bleeding symptoms as a first clinical manifestation of systemic lupus erythematosus (SLE) in an 8-year-old female. She has had multiple recurrences of her bleeding symptoms, requiring treatment with steroids, cyclophosphamide, mycophenolate mofetil, and rituximab. Her course was later complicated by development of arthritis and lupus nephritis. Her complicated course provides a new perspective on the clinical course and treatment of LAHPS. We also present a comprehensive literature review which demonstrates the difficulty in treating patients with LAHPS with underlying SLE and the variability of the clinical course and management of LAHPS depending on the age at presentation.
Assuntos
Hipoprotrombinemias , Lúpus Eritematoso Sistêmico , Humanos , Feminino , Criança , Hipoprotrombinemias/complicações , Hipoprotrombinemias/diagnóstico , Hipoprotrombinemias/tratamento farmacológico , Inibidor de Coagulação do Lúpus , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Ciclofosfamida/uso terapêutico , Hemorragia/complicações , Progressão da DoençaRESUMO
BACKGROUND Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is an exceptionally rare disease caused by prothrombin antibodies, resulting in reduced factor II levels. This disease can present with significant bleeding and is usually associated with autoimmune disorders, particularly systemic lupus erythematosus (SLE). There are currently no guidelines for the treatment of LAHPS, and corticosteroids remain the criterion standard therapy. Pseudotumor cerebri is a disease that involves an idiopathic rise in intracranial pressure in association with papilledema. The coexistence of pseudotumor cerebri with SLE is rare, with an overall incidence of 0.7%. CASE REPORT A 16-year-old male initially presented to our hospital with nausea, headaches, and decreased visual acuity. He was diagnosed with pseudotumor cerebri based on the findings of papilledema and a raised opening pressure on lumbar puncture. Three months later, he presented with macroscopic hematuria and persistent epistaxis. Further investigation revealed a prolonged activated partial thromboplastin time and prothrombin time, along with positive LA and reduced Factor II levels, resulting in a diagnosis of LAHPS. The patient received a dose of 1 mg/kg/day of prednisolone along with hydroxychloroquine, and he had a complete recovery with cessation of bleeding and normalization of laboratory parameters. CONCLUSIONS We are reporting a case of pseudotumor cerebri with a further presentation of LAHPS in a patient found to have SLE. As both associations are rare in the presence of SLE, it is vital to recognize them early to initiate adequate management and intervention to avoid life-threatening complications.
Assuntos
Síndrome Antifosfolipídica , Hipoprotrombinemias , Lúpus Eritematoso Sistêmico , Papiledema , Pseudotumor Cerebral , Adolescente , Corticosteroides/uso terapêutico , Síndrome Antifosfolipídica/complicações , Hemorragia , Humanos , Hidroxicloroquina/uso terapêutico , Hipoprotrombinemias/diagnóstico , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/etiologia , Inibidor de Coagulação do Lúpus , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Masculino , Papiledema/complicações , Prednisolona/uso terapêutico , Protrombina/uso terapêutico , Pseudotumor Cerebral/complicações , Pseudotumor Cerebral/etiologiaRESUMO
INTRODUCTION: Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare phenomenon that leads to concomitant thrombosis and hemorrhage in children with SLE. LAHPS in pediatric SLE (pSLE) has a protracted course requiring long-term immunosuppressive therapy. Due to the rarity of this syndrome and paucity of reported cases, there is lack of standardized management. We herewith report 5 children with pSLE with LAHPS.Methodology: We retrospectively reviewed clinical features, laboratory features, treatment and outcome for 5 children with lupus anticoagulant hypoprothrombinemia syndrome with SLE and a review of literature of similar cases published. RESULTS: Mean age of presentation was 10.2 ± 2.38 years (mean ± SD) and female to male ratio was 4:1. All children presented with mild to severe bleeding manifestations like gum bleed, epistaxis, hematuria, menorrhagia and subarachnoid bleed. Coagulation profile revealed prolonged PT and aPTT, with low prothrombin levels and positive Lupus anticoagulant in all children. Mixing studies were characteristic in these children. On comparing laboratory parameters majority had low C3, C4 levels, ANA and anti-DsDNA antibody positivity and three children had anticardiolipin positivity. One child had lupus nephritis along with LAHPS at presentation. All responded well to steroids and supportive measures. CONCLUSION: High index of suspicion is needed when child with lupus presents with bleeding manifestations for early diagnosis and treatment.
Assuntos
Hemorragia/etiologia , Hipoprotrombinemias/complicações , Inibidor de Coagulação do Lúpus/sangue , Lúpus Eritematoso Sistêmico/complicações , Trombose/etiologia , Adolescente , Testes de Coagulação Sanguínea/estatística & dados numéricos , Transfusão de Sangue/métodos , Criança , Diagnóstico Precoce , Feminino , Hemorragia/diagnóstico , Humanos , Hipoprotrombinemias/diagnóstico , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/terapia , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/diagnóstico , Masculino , Tempo de Tromboplastina Parcial/estatística & dados numéricos , Protrombina/análise , Estudos Retrospectivos , Esteroides/administração & dosagem , Esteroides/uso terapêutico , Trombose/diagnóstico , Resultado do TratamentoAssuntos
Inibidores dos Fatores de Coagulação Sanguínea/sangue , Hemorragia/sangue , Hipoprotrombinemias/sangue , Protrombina , Trombina , Feminino , Hemorragia/tratamento farmacológico , Humanos , Hipoprotrombinemias/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Protrombina/antagonistas & inibidores , Protrombina/metabolismo , Trombina/antagonistas & inibidores , Trombina/metabolismoRESUMO
We report two children with systemic lupus erythematosus (SLE) having severe bleeding manifestations and lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) along with a review of published cases of childhood SLE and LAHPS. We report clinical and laboratory profile of two children diagnosed with childhood SLE and LAHPS. We also conducted literature search to identify similar published cases and a review was performed. An 8-year-old girl had presented with fever, arthralgia, alopecia, anasarca and bleeding from multiple sites. She was diagnosed to have SLE based on laboratory investigations which showed anemia, thrombocytopenia, low complements, positive anti-nuclear antibody (ANA) and double standard DNA (dsDNA) antibodies. She was also found to have prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), positive lupus anticoagulant (LA) and low factor II levels. She was diagnosed to have SLE with LAHPS and treated with intravenous methylprednisolone, intravenous immunoglobulin and cyclophosphamide with good outcome. Patient 2 was a 7-year-old-boy who was diagnosed to have SLE when he presented with fever, anasarca, malar rash, arthritis and bleeding from skin and mucosa. Laboratory investigations revealed anemia, proteinuria, low complements, positive ANA and anti-dsDNA titre. Coagulation studies showed deranged PT and aPTT, positive LA and low factor II levels. He was diagnosed to have SLE with LAHPS and was treated with intravenous methylprednisolone and oral mycophenolate mofetil. Review of literature of cases with childhood SLE and LAHPS showed that there are 32 cases have been reported till date which have been summarized. LAHPS is an uncommonly identified cause of bleeding in patients with SLE and must be suspected while evaluating these children.
Assuntos
Síndrome Antifosfolipídica/diagnóstico , Hipoprotrombinemias/diagnóstico , Lúpus Eritematoso Sistêmico/diagnóstico , Síndrome Antifosfolipídica/tratamento farmacológico , Criança , Ciclofosfamida/uso terapêutico , Feminino , Humanos , Hipoprotrombinemias/tratamento farmacológico , Imunoglobulinas/uso terapêutico , Inibidor de Coagulação do Lúpus , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Masculino , Metilprednisolona/uso terapêutico , Protrombina , Resultado do TratamentoRESUMO
Lupus anticoagulant hypoprothrombinemia syndrome (LA-HPS) is a rare condition that may predispose both to thrombosis and bleeding due to positive lupus anticoagulant (LA) and factor II (FII) deficiency. It can be seen in association with infections or systemic lupus erythematosus (SLE) and may require glucocorticoids (GCs) and/or immunosuppressive medications. Pediatric LA-HPS cases in the literature and three cases that received only rituximab (RTX) for LA-HPS (in addition to GCs) at two institutions between January 2010 and June 2017 were analyzed descriptively. Pediatric LA-HPS cases (≤18 years) with bleeding or thrombotic events were included. Information obtained included demographics, presenting symptoms, diagnoses, treatments, pre-/post-treatment prothrombin time (PT)/partial thromboplastin time (PTT)/LA/FII levels, and outcomes. In addition to three LA-HPS cases identified at our institutions, as of June 2017, 37 articles reported 54 pediatric LA-HPS cases (mean age: 8 years (0.9-17 years); female/male: (2:1); viral illness 27 (50%), SLE 20 (37%), and other six (11%)). All cases had a positive LA and FII deficiency (range: 0%-40%). All cases presented with bleeding diathesis and were treated with various regimens, but there was no reported use of RTX. The purpose of this report is to describe the novel use of RTX as a steroid-sparing agent in three pediatric SLE cases and to systematically review the literature on pediatric cases of LA-HPS.
Assuntos
Hipoprotrombinemias/tratamento farmacológico , Inibidor de Coagulação do Lúpus/sangue , Rituximab/uso terapêutico , Adolescente , Criança , Feminino , Humanos , Hipoprotrombinemias/sangue , Masculino , Tempo de Tromboplastina Parcial , Tempo de Protrombina , beta 2-Glicoproteína I/imunologiaRESUMO
Lupus anticoagulant, also known as lupus antibody, is generally associated with thrombosis rather than bleeding events. Lupus anticoagulant-hypoprothrombinemia syndrome in children is rather rare but can lead to mild to life-threatening bleeding. Here, we report 3 cases of lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus. They initially presented with mucocutaneous bleedings, and subsequently developed other symptoms fulfilling the laboratory criteria for systemic lupus erythematosus. Case 2 and 3 had significant epistaxis and intracerebral hemorrhage responded to systemic corticosteroid along with fresh frozen plasma. Three cases demonstrated acquired hypoprothrombinemia with no correction of mixing studies. Case 1 had low factor X level, which has never been reported previously. In all 3 cases, their coagulogram returned to normal level after corticosteroid treatment.
Assuntos
Hipoprotrombinemias/diagnóstico , Hipoprotrombinemias/etiologia , Inibidor de Coagulação do Lúpus/imunologia , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/imunologia , Adolescente , Contagem de Células Sanguíneas , Testes de Coagulação Sanguínea , Medula Óssea/patologia , Criança , Feminino , Humanos , Hipoprotrombinemias/tratamento farmacológico , Imunossupressores/uso terapêutico , Inibidor de Coagulação do Lúpus/sangue , Lúpus Eritematoso Sistêmico/sangue , Troca Plasmática , Síndrome , Resultado do TratamentoRESUMO
: We report a 14-year-old girl who presented with subdural hematoma and a deranged coagulation profile suggestive of an inhibitor. Investigations revealed prothrombin deficiency along with positivity for antiphospholipid antibodies, which improved with steroid therapy. Bleeding diathesis in children and adolescents commonly results from thrombocytopenia, platelet function disorders, or coagulation factor deficiency; whereas bleeding because of coagulation factor inhibitors are extremely rare in this age group. This case also highlights the uncommon presentation of antiphospholipid antibody syndrome, as they often present with thrombosis or pregnancy complications rather than bleeding.
Assuntos
Síndrome Antifosfolipídica/complicações , Hematoma Subdural/complicações , Hipoprotrombinemias/complicações , Inibidor de Coagulação do Lúpus/sangue , Adolescente , Síndrome Antifosfolipídica/sangue , Síndrome Antifosfolipídica/tratamento farmacológico , Feminino , Hematoma Subdural/sangue , Hematoma Subdural/tratamento farmacológico , Humanos , Hipoprotrombinemias/sangue , Hipoprotrombinemias/tratamento farmacológico , Esteroides/uso terapêuticoRESUMO
Lupus anticoagulant-hypoprothrombinemia syndrome is a rare condition characterized by the association of acquired factor II deficiency and lupus anticoagulant. Contrary to classical antiphospholipid syndrome, it may cause severe life-threatening bleeding (89% of published cases). We report a patient, positive for antidomain I antibodies, with initially primary lupus anticoagulant-hypoprothrombinemia syndrome without previous clinical manifestation or underlying systemic disease. Five years later, he experienced the first systemic lupus erythematous flare. Within a few days, catastrophic antiphospholipid syndrome was diagnosed with heart, liver and kidney involvement. The patient recovered under pulse steroids, intravenous heparin and intravenous immunoglobulins.
Assuntos
Síndrome Antifosfolipídica/diagnóstico , Hipoprotrombinemias/diagnóstico , Inibidor de Coagulação do Lúpus/sangue , Lúpus Eritematoso Sistêmico/diagnóstico , Adulto , Anticorpos Antifosfolipídeos/sangue , Anticorpos Antifosfolipídeos/imunologia , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/tratamento farmacológico , Síndrome Antifosfolipídica/imunologia , Heparina/uso terapêutico , Humanos , Hipoprotrombinemias/complicações , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/imunologia , Imunoglobulinas Intravenosas/uso terapêutico , Rim/imunologia , Rim/metabolismo , Rim/patologia , Fígado/imunologia , Fígado/metabolismo , Fígado/patologia , Inibidor de Coagulação do Lúpus/imunologia , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/etiologia , Lúpus Eritematoso Sistêmico/imunologia , Masculino , Miocárdio/imunologia , Miocárdio/metabolismo , Miocárdio/patologia , Esteroides/uso terapêuticoRESUMO
Antiphospholipid antibody-positive patients can develop bleeding due to capillaritis, microthrombosis, antiprothrombin antibodies, thrombocytopenia, and/or excessive antithrombotic therapy. Clinical characteristics of patients, e.g., renal impairment, elderly, or concomitant medications, are closely related to the risk of bleeding. The management of bleeding in antiphospholipid antibody (aPL)-positive patients is challenging due to the baseline increased risk of thrombosis. If anticoagulation is stopped, it should be restarted as soon as possible once the acute bleeding is controlled; the continuation of anticoagulation despite active bleeding may be required in selected cases. High-dose corticosteroid is the mainstay treatment for diffuse alveolar hemorrhage, lupus anticoagulant-hypoprothrombinemia syndrome, and severe thrombocytopenia; immunosuppressive drugs are also required to improve the long-term outcomes. Hydrocortisone is critical in adrenal hemorrhage patients due to concomitant adrenal insufficiency; despite bleeding, anticoagulation should be maintained as much as possible. Plasma exchange should be considered in catastrophic antiphospholipid syndrome patients with concurrent bleeding. This article will review the causes of bleeding in aPL-positive patients as well as the management strategies.
Assuntos
Síndrome Antifosfolipídica/complicações , Hemorragia/etiologia , Doenças das Glândulas Suprarrenais/diagnóstico , Doenças das Glândulas Suprarrenais/tratamento farmacológico , Doenças das Glândulas Suprarrenais/etiologia , Hemorragia/diagnóstico , Hemorragia/tratamento farmacológico , Humanos , Hipoprotrombinemias/diagnóstico , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/etiologia , Pneumopatias/diagnóstico , Pneumopatias/tratamento farmacológico , Pneumopatias/etiologia , Alvéolos PulmonaresAssuntos
Hemorragia Cerebral/etiologia , Hipoprotrombinemias/complicações , Hipoprotrombinemias/tratamento farmacológico , Inibidor de Coagulação do Lúpus/uso terapêutico , Adulto , Biópsia , Feminino , Seguimentos , Humanos , Angiografia por Ressonância Magnética , Imageamento por Ressonância Magnética , Transtornos da Motilidade OcularRESUMO
Hypoprothrombinemia associated with a lupus anticoagulant (LA) was first reported in the literature over 50 years ago. The hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) is a rare bleeding diathesis that has been associated with LAs in adult and paediatric patients with systemic lupus erythematosus (SLE) and with transient LAs due to other causes. There are no standard recommendations for treating haemorrhage associated with this syndrome. Herein, we report a patient with SLE and HLAS who achieved a durable remission following treatment with intravenous immune globulin (IVIG), prednisone and rituximab.
Assuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Síndrome Antifosfolipídica/tratamento farmacológico , Hipoprotrombinemias/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Inibidor de Coagulação do Lúpus , Adulto , Quimioterapia Combinada/métodos , Feminino , Glucocorticoides/uso terapêutico , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Prednisona/uso terapêutico , Rituximab , Resultado do TratamentoRESUMO
Prothrombin (Factor II, FII) deficiency is an extremely rare autosomal recessive condition with an estimated incidence of 1:2 million. As severe and life-threatening bleeding is rare in FII deficiency, on demand therapy with administration of prothrombin complex concentrates (PCCs) or fresh frozen plasma is generally performed, and prophylactic therapy for FII deficiency has been reported in only three cases. Thus, its optimal dosage and schedule has remained uncertain. Here we report a case of severe prothrombin deficiency with a novel frameshift mutation of the F2 gene, who was started on prophylactic administration.
Assuntos
Fatores de Coagulação Sanguínea/uso terapêutico , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/genética , Protrombina/genética , Adulto , Sequência de Bases , Mutação da Fase de Leitura , Humanos , Recém-Nascido , Masculino , Dados de Sequência Molecular , LinhagemRESUMO
Vitamin K1 (phytomenadione or phytonadione) is a fat soluble vitamin used to treat certain coagulation disorders. Intra muscular injection of vitamin K1 can occasionally be complicated by different types of skin reactions: erythematous plaques, urticarial rashes or scleroderma-like lesions at the injection site. We report the case of a 52-year-old man presenting with 2 symmetrical erythematous-infiltrated scleroderma-like plaques localized on the right and left lower trunk. To correct the coagulation deficiency with hypoprothrombinemia developed as a consequence of HCV+ hepatitis, the patient was on vitamin K1 therapy, administered by i.m. injection (10 mg Vitamin K1/1 ml) once a day for 2 weeks. Three months after treatment interruption, ivory indurated morphoeiform plaques developed at the injection sites, assuming the typical appearance of a "cowboy's belt with revolver". The scleroderma-like lesions persisted 2 years after vitamin K1 withdrawal. We report this case to highlight the possibility that vitamin K1 injections can occasionally be complicated by different types of skin reactions such as sclerodermatous plaques. Due to the delay in the onset, to the variable clinical picture, to the persistence after therapy interruption, this kind of lesions can represent a tricky diagnostic challenge and in spite of different treatments can endure for years.
Assuntos
Esclerodermia Localizada/induzido quimicamente , Vitamina K 1/efeitos adversos , Diabetes Mellitus Tipo 2/complicações , Eritema/induzido quimicamente , Hepatite C Crônica/complicações , Humanos , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/etiologia , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , Esclerodermia Localizada/complicações , Esclerodermia Localizada/patologia , Vitamina K 1/administração & dosagem , Vitamina K 1/uso terapêuticoRESUMO
Vitamin K1 is frequently used in the treatment and prevention of hypoprothrombinemia and hemorrhagic disease of the newborn. It also serves as an antidote to anticoagulants. Erythematous, indurated, pruritic plaques uncommonly occur in adults after intramuscular injection with vitamin K1. We present a case of a localized cutaneous reaction to intramuscular vitamin K1 in a peripartum patient with acute fatty liver of pregnancy. The history and clinical presentation of our case is presented with a discussion of the pathogenesis pathogenesis of vitamin K1 and available treatment for this condition.
Assuntos
Toxidermias/etiologia , Hipersensibilidade a Drogas/etiologia , Fígado Gorduroso/complicações , Complicações na Gravidez/tratamento farmacológico , Transtornos Puerperais/etiologia , Vitamina K 1/efeitos adversos , Doença Aguda , Eczema/induzido quimicamente , Eritema/induzido quimicamente , Feminino , Humanos , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/etiologia , Injeções Intramusculares , Gravidez , Vitamina K 1/administração & dosagem , Adulto JovemRESUMO
Beriplex P/N, a prothrombin complex concentrate derived from pooled human plasma, contains the vitamin K-dependent coagulation factors II, VII, IX and X, and the vitamin K-dependent coagulation inhibition proteins C and S. Intravenous Beriplex P/N provided rapid and sustained normalization of elevated international normalized ratios and controlled bleeding in adult patients participating in several prospective, noncomparative clinical studies (n = 8-43), with these data supported by clinical experience during its use over more than a decade. Based on extensive clinical experience, Beriplex P/N is also effective in the treatment of congenital deficiency of any of the vitamin K-dependent coagulation factors when purified specific coagulation factor products are not available. Over a decade of clinical experience and more limited data from clinical studies have shown that intravenous infusions of Beriplex P/N were generally well tolerated in adult patients with acquired or congenital deficiencies of the vitamin K-dependent coagulation factors. To date, there have been no proven cases of viral transmission reported in any published studies.
Assuntos
Fator IX/uso terapêutico , Fator VII/uso terapêutico , Fator X/uso terapêutico , Hemorragia/tratamento farmacológico , Hipoprotrombinemias/tratamento farmacológico , Protrombina/uso terapêutico , Deficiência de Vitamina K/tratamento farmacológico , Anticoagulantes/uso terapêutico , Combinação de Medicamentos , HumanosRESUMO
The presence of lupus anticoagulant is associated with an elevated risk of venous and arterial thrombosis, and recurrent miscarriages as well. For some cases, this disease can present with bleeding as a consequence of lupus anticoagulant hypoprothrombinemia (LAHPS). LAHPS is a rare disease and it is reported to be most frequent in young females with/without systemic lupus erythematosus or in healthy children who are suffering with a viral infection. In such cases, steroid therapy is usually effective in normalizing the biological abnormalities and controlling the bleeding problems. A 34-year-old previously healthy man was admitted to our department because of his prolonged coagulation times; these abnormalities were discovered before performing orthopedic surgery. The prothrombin time (PT) was 15.2 sec, and the activated partial thromboplastin time (APTT) was 37.7 sec. A 1:1 dilution of patient plasma with normal plasma nearly corrected the PT, but this failed to correct the APTT. Evaluation of the clotting factors revealed decreased levels of factors II, V, VIII, IX and XI. The presence of LA was demonstrated by the dRVVT test, and the patient was diagnosed with LAHPS. He was successfully treated with corticosteroid before performing the orthopedic surgery.
Assuntos
Hipoprotrombinemias/diagnóstico , Inibidor de Coagulação do Lúpus/imunologia , Lúpus Eritematoso Sistêmico/diagnóstico , Corticosteroides/uso terapêutico , Adulto , Humanos , Hipoprotrombinemias/tratamento farmacológico , Hipoprotrombinemias/imunologia , Hipoprotrombinemias/fisiopatologia , Lúpus Eritematoso Sistêmico/imunologia , Lúpus Eritematoso Sistêmico/fisiopatologia , Masculino , Tempo de Tromboplastina Parcial , Cuidados Pré-Operatórios , Tempo de ProtrombinaRESUMO
PURPOSE: A case of cefazolin-induced hypoprothrombinemia in a patient with renal failure is reported. SUMMARY: A 50-year-old African-American woman was transferred from the orthopedics service to the internal medicine service for management of acute renal failure. Before her transfer, she had spinal surgery and subsequently developed a wound infection complicated by Escherichia coli bacteremia. After trials of multiple antibiotics, she developed acute interstitial nephritis and renal failure. On the day of her transfer to the internal medicine service, i.v. cefazolin sodium 1 g was administered every 24 hours to eradicate the E. coli detected in blood cultures. Her baseline International Normalized Ratio (INR) was 1.3. On day 7 of cefazolin therapy, her INR increased to 4.0. Because of her recent history of bleeding and hypotension, vitamin K 10 mg i.v. was administered, followed by 5 mg orally for the next two days. Her INR decreased and normalized at 1.1. The patient had no changes to other drug therapies and had no medical conditions known to independently affect prothrombin time during this episode. The score on the Naranjo et al. adverse-event probability scale revealed a probable relationship between cefazolin and hypoprothrombinemia in this patient. CONCLUSION: A patient with a postsurgery wound infection and acute renal failure developed hypoprothrombinemia after receiving cefazolin for seven days.